Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States

American Journal of Health-System Pharmacy(2021)10.1093/ajhp/zxaa426Source: DataRank Database

Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States is a research paper published in American Journal of Health-System Pharmacy (2021). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.31)OA: bronzeTopics (92)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Atheer Dairem,William J Moore ORCID,Anooj Shah,Michael Postelnick,Melissa E. Badowski ORCID

Live enrichment

PubMed:33537767 PMC:PMC7929420 OpenAlex:https://openalex.org/W3127612571

National Center for Advancing Translational Sciences

Grant: UL1TR001422

National Institutes of Health

Grant: 5UL1TR001422-04

Northwestern University Clinical and Translational Science Institute (NUCATS)

National Institutes of Health

FWCI

0.31

Citation Percentile

0.6%

Citation Trend

2020

2021

2022

2023

2024

bronzeLicense: OUP Standard Publication Reuse

journalhttps://academic.oup.com/ajhp/article-pdf/78/7/568/36635468/zxaa426.pdf

publisherhttps://academic.oup.com/ajhp/article-pdf/78/7/568/36635468/zxaa426.pdf

publisherhttp://academic.oup.com/ajhp/advance-article-pdf/doi/10.1093/ajhp/zxaa426/36187184/zxaa426.pdf

publisherhttp://academic.oup.com/ajhp/article-pdf/78/7/568/36635468/zxaa426.pdf

journalhttps://doi.org/10.1093/ajhp/zxaa426

Fields of Study

COVID-19 Clinical Research StudiesPharmacological Receptor Mechanisms and EffectsSARS-CoV-2 and COVID-19 Research03 medical and health sciences0302 clinical medicineAdolescentAdultAgedAged, 80 and overAntiviral AgentsChildChild, PreschoolDrug Therapy, CombinationDrug-Related Side Effects and Adverse ReactionsFemaleHumansHydroxychloroquineInfantInfant, NewbornMaleMiddle AgedPandemicsPrevalenceRetrospective StudiesSARS-CoV-2United StatesYoung AdultCOVID-19 Drug Treatment

MeSH Terms

SARS-CoV-2COVID-19 Drug TreatmentAdolescentAdultAgedAged, 80 and overAntiviral AgentsChildChild, PreschoolDrug Therapy, CombinationFemaleHumansHydroxychloroquineInfantInfant, NewbornMaleMiddle AgedRetrospective StudiesUnited StatesPrevalenceYoung AdultPandemicsDrug-Related Side Effects and Adverse Reactions

Keywords

TimelinePandemicCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineVirologyDrugGeographyOutbreakInternal medicinePharmacologyInfectious disease (medical specialty)DiseaseAdverse drug reactionSupportive CareObservational StudyMedication SafetyCovid-19Sars-cov-2AdultMaleAdolescentDrug-Related Side Effects and Adverse ReactionsAntiviral AgentsPrevalenceHumansChildPandemicsAgedRetrospective StudiesAged, 80 and overClinical ReportHealth PolicyInfant, NewbornInfantMiddle AgedChild, PreschoolDrug Therapy, CombinationFemaleHydroxychloroquine

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being